NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026

Core Insights - NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. announced that an abstract for their investigational drug SIM0505 has been accepted for presentation at the ASCO 2026 meeting, highlighting its potential in treating advanced solid tumors, particularly platinum-resistant ovarian cancer [1][2]. Company Overview - NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, utilizing targeted therapies such as antibody-drug conjugates [4]. - Simcere Zaiming is an oncology-focused biopharmaceutical company, a subsidiary of Simcere Pharmaceutical Group Limited, established in 2023, dedicated to developing groundbreaking therapies for cancer patients globally [5]. Product Details - SIM0505 is a novel antibody drug conjugate targeting Cadherin-6 (CDH6) and features a proprietary topoisomerase 1 inhibitor (TOPOi) payload, designed for broad anti-tumor activity and improved therapeutic potential [3]. - The ongoing Phase 1 study (NCT06792552) is evaluating SIM0505's efficacy in advanced solid tumors, with a specific focus on platinum-resistant ovarian cancer [2][3].